Major shareholder notification
18 août 2023 14h40 HE
|
Coloplast A/S
Major shareholder notification Reference is made to the press release issued by Coloplast A/S on 21 June 2023 regarding the intention of Coloplast A/S' largest shareholders, Niels Peter Louis-Hansen,...
Coloplast A/S - Announcement no. 04/2023 - Interim Financial Report, 9M 2022/2023
17 août 2023 01h28 HE
|
Coloplast A/S
9M 2022/23Interim financial results, 9M 2022/231 October 2022 - 30 June 2023 Coloplast delivered Q3 organic growth of 8% and 28% EBIT margin1). Reported revenue in DKK grew 4% to...
Coloplast A/S - Selskabsmeddelelse nr. 03/2023 - Coloplast offentliggør aftale om køb af Kerecis og hæver de langsigtede vækstforventninger
07 juil. 2023 02h26 HE
|
Coloplast A/S
Coloplast har indgået en aftale om at købe Kerecis, en innovativ og hurtigtvoksende virksomhed inden for ’biologics’ sårplejesegmentet, for op til USD 1,3 mia. (omkring 8,9 mia. kr.), hvoraf USD 1,2...
Coloplast A/S - Announcement no. 03/2023 - Coloplast announces agreement to acquire Kerecis and raises long-term growth expectations
07 juil. 2023 02h26 HE
|
Coloplast A/S
Coloplast has signed an agreement to acquire Kerecis, an innovative, fast-growing company in the biologics wound care segment, for up to USD 1.3 billion (around DKK 8.9 billion), of which USD 1.2...
Hovedaktionær og Fond vil sikre Coloplast med nyt holdingselskab
21 juin 2023 12h05 HE
|
Coloplast A/S
Hovedaktionær i Coloplast A/S, Niels Peter Louis-Hansen, vil som led i et generationsskifte stifte et holdingselskab. Selskabet stiftes sammen med Coloplasts næststørste aktionær Aage og Johanne...
Coloplast A/S - Selskabsmeddelelse nr. 02/2023 - Regnskabsmeddelelse, 1. halvår 2022/23
11 mai 2023 01h30 HE
|
Coloplast A/S
H1 2022/23 Regnskabsmeddelelse, 1. halvår 2022/23 1. oktober 2022 – 31. marts 2023 Coloplast leverede en organisk vækst på 8% og en overskudsgrad på 28% i andet kvartal1). Den...
Coloplast A/S - Announcement no. 02/2023 - Interim Financial Report, H1 2022/23
11 mai 2023 01h30 HE
|
Coloplast A/S
H1 2022/23 Interim financial results, H1 2022/23 1 October 2022 - 31 March 2023 Coloplast delivered Q2 organic growth of 8% and 28% EBIT margin1). Reported revenue in DKK was up by 10%. ...
New clinical study demonstrates significant improvement in pulmonary health and related symptoms when using Provox® Life™
24 avr. 2023 03h30 HE
|
Coloplast A/S
A new multi-center, prospective, two-phase clinical trial1 supported by Atos Medical, a leading company in laryngectomy care, demonstrates a significant improvement in cough and sputum symptoms,...